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Key questions
What is already known?
 ► High contraceptive discontinuation contributes to 
high unmet need in sub-Saharan Africa, and short-
term gaps in method use have been documented in 
Malawi and South Africa.
What are the new findings?
 ► Delays in obtaining repeat pills and injections are 
common in Senegal, exposing contraceptive users 
to pregnancy.
 ► Widespread covert use, illiteracy, cost and availabil-
ity of family planning services limit women’s ability 
to attend the facility on time.
What do the new findings imply?
 ► Women who are most likely to have delayed appoint-
ments could be identified in health facilities and pro-
vided with additional support.
 ► In the short term, innovative appointment reminder 
strategies should be tailored to contexts of high illit-
eracy and covert use.
AbsTrACT
Introduction High discontinuation rates of contraceptive 
methods have been documented in sub-Saharan Africa. 
However, little is known about gaps within individual 
episodes of method use, despite their implications for 
unintended pregnancies. The objective of this mixed 
methods study was to examine the prevalence of, and 
explore the factors contributing to, delays in repeat 
appointments for pills and injectables in Senegal.
Methods First, we constructed a longitudinal data set 
of women’s contraceptive consultations using routine 
records from 67 facilities in Senegal. Consultations for 
pills and injectables were classified as on time, delayed or 
with unknown delay status based on time since previous 
appointment. We described the prevalence of delayed 
appointments and used backward stepwise regression 
to build a mixed-effects model to investigate risk factors 
for delay. Second, we conducted workshops with family 
planning (FP) providers, and indepth interviews and focus 
group discussions with women of reproductive age, to 
explore factors contributing to delays.
results Almost one-third (30%) of appointments for 
pills and injectables were delayed, resulting in risk of 
pregnancy. Previous delay, pill use, lower educational level, 
higher parity, third and subsequent visits, and Islamic faith 
were independently predictive of delays (p<0.04 for all). 
Although women’s ‘forgetfulness’ was initially mentioned 
as the main reason for delays by women and providers, 
examining the routines around appointment attendance 
revealed broader contextual barriers to timely refills—
particularly widespread covert use, illiteracy, financial cost 
of FP services and limited availability of FP services.
Conclusion Delays in obtaining repeat pills and injections 
are common among contraceptive users in Senegal, 
exposing women to unintended pregnancies. Strategies to 
reduce such delays should move beyond a narrow focus 
on individual women to consider contraceptive behaviour 
within the broader socioeconomic and health systems 
context. In particular, effective interventions addressing low 
acceptability of contraception and appointment reminder 
strategies in high illiteracy contexts are needed.
InTroduCTIon
Pills and injectables are two of the most popular 
contraceptive methods in sub-Saharan Africa: 
more than half of contraceptive users relied 
on these two methods in 29 of 43 countries 
with Demographic and Health Survey (DHS) 
data.1 Among the advantages explaining their 
popularity, they are less invasive than longer 
acting methods and reversible without assis-
tance from a health provider—a particular 
benefit in contexts where desired fertility is 
high and contraception is primarily used for 
spacing births, such as West Africa.2 3
However, one important constraint of 
pills and injectables is the need for regular 
refills to effectively protect against unwanted 
pregnancy. Women using progesterone-only 
injectables need a reinjection within 13 
weeks,4 5 although they are not at risk of preg-
nancy until several weeks later.6 For pill users, 
the effectiveness period depends on how 
many pill packs—each covering one 28-day 
cycle—are provided, varying with setting and 
duration of use.
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Senegal has experienced a rapid increase in modern 
contraceptive use in recent years, from 12% among 
married women in 2010–2011 to 23% in 2016.7 8 More 
than half of modern contraceptive users rely on inject-
ables (35%) and pills (20%).8 The rates of unintended 
pregnancies are high in Senegal, with up to one-third of 
births estimated to be unplanned or unwanted.7 9 The 
extent to which the recent increase in contraceptive 
use will be translated into a reduction in unintended 
pregnancies depends in part on continuity of method 
use, including the extent of interruptions in use. Gaps 
in contraceptive coverage are particularly a concern for 
short-acting methods requiring regular refills by women, 
leading to more opportunities for lapses in adherence.
To date, much of the evidence on continuity of use 
relates to women discontinuing contraception altogether 
or switching to another method. High rates of discontin-
uation for method-related reasons (such as side effects) 
have been found for pills and injectables in low-income 
and middle-income countries,10 including Senegal where 
one-third of women discontinue their method within a 
year and unmet need is high after discontinuing.11 12 Much 
less evidence is available on gaps in continuity within the 
same episode of method use. Temporary discontinuation 
has been documented among inner-city adolescents in 
the USA and new contraceptive users in South Africa, 
with gaps lasting 7–8 months on average.13 14 Shorter 
term interruptions have also been demonstrated in the 
USA, where around half of women had delays in refilling 
prescriptions in the first 3 months after initiation.15
Few large-scale data sources of contraceptive appoint-
ments or refills are available in low-income countries. 
Calendar data—based on women’s self-reported contra-
ceptive use month by month for the preceding 3–5 years, 
widely available in DHS—are poorly suited for analysing 
gaps in contraceptive use, since women may forget or not 
report them. Prospectively recorded data of the timing 
of contraceptive refills are needed to examine gaps in 
continuity, yet few longitudinal studies of contraceptive 
consultations have been conducted. In Malawi, only 51% 
of injectable users received their first reinjection within 
13 weeks,16 and 16%–25% of women returned more than 
2 weeks late for injections in South Africa,17 suggesting 
that delayed refills for short-acting methods may also be 
widespread in other sub-Saharan settings.
Moreover, reasons for any gaps in continuity are 
poorly understood. Women seeking to refill short-acting 
methods face a number of financial, geographical and 
other barriers to accessing contraception in sub-Saharan 
Africa,18 19 at every appointment. In South Africa, the 
most common reason for attending appointments late 
was conflicting work or family priorities, followed by 
forgetting and lacking transport or money.17 Qualitative 
evidence in particular is needed to further understand 
the reasons behind ‘missed appointments’ in other coun-
tries, including Senegal.
The recent rise in contraceptive use in Senegal is under-
scored by a large increase in the number of injectable and 
pill users. Existing barriers to family planning (FP) access 
in Senegal20 21 suggest that gaps in contraceptive conti-
nuity may be common there. Ethnographic data have also 
shown that despite global and national commitments, FP 
programmes in Senegal have sometimes failed to address 
the socioeconomic challenges faced by women in their 
everyday reproductive lives.22 Mixed methods studies 
are useful in gaining a fuller understanding of indi-
vidual and contextual factors influencing contraceptive 
behaviour.23–25 The objective of this study is to examine 
the prevalence of, and explore the reasons for, delays in 
appointments for pills and injectables in Senegal, using a 
mixed quantitative and qualitative approach.
MeTHods
study setting and design
Senegal counts 3.5 million women of reproductive age.26 
The public health system follows a pyramid model, with 
the 14 regional medical offices overseeing the health 
centre and health posts in subregional districts.27 The vast 
majority of modern contraceptive users in Senegal obtain 
their methods from public facilities, including 77% in 
health centres and posts.8 FP providers in these facilities 
record each consecutive visit on the same consultation 
card for individual women. In addition, women are given 
an appointment reminder card with the next scheduled 
appointment date. FP products are sold at subsidised cost 
in public facilities, and women may also be charged for 
auxiliary products (such as syringes for injections).
This study used information collected for the evalua-
tion of a supply chain intervention, the Informed Push 
Model, rolled out nationally in a staggered scale-up 
between 2012 and 2015. Under the Informed Push 
Model, third-party private logisticians were contracted to 
undertake stock inventories and distribute contraceptives 
to all public health centres and health posts in Senegal, 
with the aim of reducing contraceptive stockouts.28
As part of this evaluation, we collected qualitative and 
quantitative information to better understand barriers 
to contraceptive use in Senegal. Preliminary analysis of 
facility records suggested that women often missed their 
follow-up contraception appointments, and regular 
attendance also emerged as a concern for FP providers in 
qualitative workshops. Based on these concurrent obser-
vations, we incorporated the topic of appointment atten-
dance in the interview and focus group guides to enable 
a mixed methods study of barriers to regular attendance.
Quantitative methods
Data source
In total, data on FP consultations were collected from 
72 public facilities in 9 regions. Data were collected in 
July and August 2016 by surveyor teams including at 
least one medical doctor and midwife. Public health 
centres and health posts were selected randomly using 
a stratified sampling design (regions sampled by simple 
random sample from zones, districts sampled by simple 
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Table 1 Classification of timeliness of consultation by method
Classification of appointment 
timeliness Pill Injectable
On time—women not exposed to 
pregnancy
Up to 28 days multiplied by the number of 
pill packs received at last appointment.
 ► Up to 13 weeks since last appointment.
 ► Or within 4-week grace period with no 
delay at previous appointment.
Delayed—women exposed to pregnancy Later than 28 days multiplied by the number 
of pill packs received at last appointment, 
and less than 3 weeks after scheduled 
appointment date.
 ► After 4-week grace period.
 ► Or within 4-week grace period with a 
delay at previous appointment.
Delay status unknown Later than 3 weeks after the scheduled 
appointment date.
 ► Later than 11 weeks after the scheduled 
appointment date.
random sample from regions). In each selected district, 
the district health centre was included, as well as three 
randomly selected health posts.
Information on facility characteristics and the number 
of FP providers was collected from facility managers 
using a questionnaire designed for this study. Data were 
extracted from routine, standardised FP consultation 
cards for all women attending an FP consultation in April, 
May or June 2016. These consultation cards record infor-
mation on sociodemographic characteristics, method 
chosen at first appointment, and the date and units 
received at each consecutive appointment for the same 
woman at the facility. A standardised FP record manage-
ment system is promoted by district reproductive health 
coordinators, whereby consultation cards are organised 
according to the date of next scheduled appointment 
(eg, third month after injection), facilitating the identifi-
cation of our study sample. Data on months with recorded 
stockouts for contraceptive products were also extracted 
from stock cards, and monthly number of consultations 
was extracted from FP registers.
All information from routine records was captured 
in facilities using handheld scanners and subsequently 
entered into a database. Extensive data quality checks 
were performed during data collection and entry, 
including comparing data entered with scanned records 
for approximately 5% of all consultation cards.
Data preparation and definition of delay
We constructed a longitudinal data set of FP consulta-
tions linked by women using routine consultation cards. 
Consultations in which women received an injection or 
pill pack(s), with known current and subsequent visit 
dates, were included in the analysis and classified into 
three categories: (1) those with a subsequent consulta-
tion whose timing did not expose women to pregnancy 
(‘on time’), (2) those with a delayed subsequent consul-
tation exposing women to pregnancy (‘delayed’), and 
(3) those with a subsequent consultation of unknown 
delay status (table 1). For pills, consultations were consid-
ered on time if they occurred before the woman’s pill 
supply was exhausted, and delayed thereafter. Consulta-
tions with delays longer than 3 weeks were considered of 
unknown delay status, since women may have obtained 
contraceptive pills elsewhere.
Although repeat depot medroxyprogesterone acetate 
(DMPA) injections (including the two injectables distrib-
uted in Senegal, Depo Provera and Sayana Press) ‘can 
be given up to four weeks late without requiring addi-
tional contraceptive protection, this does not mean that 
the regular DMPA injection interval can be extended by 
four weeks’.6 Injectable consultations were considered on 
time if they occurred before the end of the 13-week effec-
tiveness period, or within the 4-week grace period with 
no delay at the previous injection. They were considered 
delayed if they occurred after the 4-week grace period, 
or within the 4-week grace period if the previous consul-
tation was also delayed. The delay status was considered 
unknown if the visit occurred more than 11 weeks after 
the end of the effectiveness period, since women may 
have received an injection elsewhere.
statistical analysis
The analysis sample included consultations in the 3 years 
prior to data collection (July 2013–June 2016) to describe 
the current situation regarding delayed appointments. 
The characteristics of facilities and women included in 
the sample were described, as well as the delay status of 
consultations overall, and for each method separately. We 
used three-level mixed-effects logistic regression models 
(consultations nested among women nested among facil-
ities) to identify women and facility characteristics associ-
ated with delayed consultations, excluding consultations 
with unknown delay status. Variables associated with a 
delayed consultation in bivariate models with a p value 
≤0.25 were included in the full multivariable model. We 
used Spearman correlations to examine multicolline-
arity in the full model. Manual backward stepwise elim-
ination based on Wald tests was used to reduce the full 
model to a more parsimonious final model, using records 
with complete data for the variables included in the full 
model. Variable elimination stopped when all predictors 
had a p value ≤0.1. The final model presented includes 
all records with complete data for included variables. 
Forward stepwise regression was performed as a sensi-
tivity analysis.
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Figure 1 Selection of women and consultations in the sample for analysis.
Qualitative methods
Data source
The qualitative data source used in this study consists of 2 
participatory workshops with 12 FP providers (nurses and 
midwives) conducted in July 2016, as well as 8 focus groups 
and 112 indepth interviews with women of reproduc-
tive age conducted between September and December 
2016, in 11 of the 14 regions of Senegal. Sampling was 
purposive to represent urban and rural areas, distance to 
nearest facility, and different cultural and socioeconomic 
contexts. Some women participating in focus groups or 
interviews may also be included in the quantitative anal-
ysis; however, participants were anonymised and uniden-
tifiable between study arms. Interview and focus group 
guides were informed by a desk review of peer-reviewed 
and grey literature (in French and English) on FP in 
Senegal, and by exploratory work conducted through 
preliminary discussions with FP stakeholders and visits 
of FP facilities. Interview guides were designed to allow 
unexpected issues to emerge.
Analysis
Verbatim transcripts of interviews, workshops and focus 
groups conducted in Wolof were translated into French 
and independently coded by the study researchers along 
key themes. Deductive codes were derived from the inter-
view guide, and inductive codes were developed through 
analysis of the selected transcripts. Codes were further 
developed using qualitative software and agreed on 
collectively between research assistants and supervisors. 
For the scope of this paper, we focused on documenting 
the routines surrounding FP appointments to better 
understand contextual reasons for delayed attendance, 
through a thematic analysis of workshop, interview and 
focus group transcripts.
resulTs
Quantitative findings
Description of sample of women and consultations
In total, 6800 women attended an FP consultation in April, 
May or June 2016 in the facilities sampled. The reasons 
for excluding women and consultations are described 
in figure 1. The sample used for analysis included 4005 
women with 14 806 consultations (59% of 25 222 total 
consultations among these women) between July 2013 and 
June 2016 during which they received pills or injectables.
The vast majority of contraceptive users were currently 
married (88%) and Muslim (90%), and most women had 
at least two children (73%; table 2). Almost half of women 
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Table 2 Description of women in the sample (N=4005)
Characteristics n (%)
Age at most recent visit
  15–19 216 (5.4)
  20–29 1580 (39.5)
  30–39 1347 (33.6)
  40–50 456 (11.4)
  Missing 406 (10.1)
Living children at first visit
  0–1 776 (19.4)
  2–3 1421 (35.5)
  4+ 1516 (37.9)
  Missing 292 (7.3)
Ethnicity
  Wolof 1549 (38.7)
  Serere 418 (10.4)
  Toucouleur 537 (13.4)
  Mandingue/Diola/Autres 1292 (32.3)
  Missing 209 (5.2)
Religion
  Muslim 3604 (90.0)
  Christian or other 198 (4.9)
  Missing 203 (5.1)
Marital status
  Married 3512 (87.7)
  Single/Widowed/Divorced/Separated 280 (7.0)
  Missing 213 (5.3)
Occupation
  Housewife 2679 (66.9)
  Student/Other 922 (23.0)
  Missing 404 (10.1)
Education
  None 1786 (44.6)
  Primary 997 (24.9)
  Secondary+ 783 (19.6)
  Missing 439 (11.0)
Table 3 Description of facilities in the sample (N=67)
Characteristics n
Facility type
  Health centre 16
  Health post 51
Location
  Rural 48
  Urban 19
Number of FP consultations per month (all methods)
  0–30 27
  30–80 16
  80 or more 21
Number of FP providers
  1–2 42
  3–4 11
  5 or more 12
Percentage of months with stockouts
  0%–15% 33
  15%–30% 25
  30% and above 7
FP, family planning.
(45%) had not received any formal education. Between 
5% and 11% of women had missing information on socio-
demographic variables. Facility characteristics of the 16 
health centres and 51 health posts attended by women in 
the sample are described in table 3.
Prevalence of delays
A similar proportion of appointments for pills and injecta-
bles were ‘on time’ (36% and 35%, respectively) (table 4). 
A further 30% of appointments for injectables were within 
the 4-week grace period with no delay at the previous visit, 
meaning in total two-thirds of appointments for injectables 
were ‘on time’, with no exposure to pregnancy. However, 
27% of appointments for injectables were delayed with the 
effect of exposing women to pregnancy, either because they 
occurred after the 4-week grace period (5%) or because of 
consecutive delays at the current and previous visits (22%). 
Delays were more common for pill appointments (44%) 
than injectables (27%). Around 8% of injectable visits had 
an unknown delay status, compared with 20% for pills. 
Overall, the timing of 30% of all visits for pills and inject-
ables exposed women to pregnancy, while 60% were on 
time.
Predictors of delayed consultations
We examined risk factors for delays among consultations 
with known delay status. In bivariate analyses age, parity, 
ethnicity, religion, marital status, education, visit number, 
method received, previous delay, facility type, stockout 
level and region were associated with delayed consultation 
(p≤0.25; table 5). There was no association between delayed 
appointments and women’s occupation, facility location, 
number of FP providers or FP consultation volume.
In the final model, previous delay, pill use, lower educa-
tional level, higher parity, third visits and Islamic faith 
were predictive of a delayed consultation (p<0.04 for all). 
The strongest predictor was having experienced a delay at 
a previous consultation (OR=7.54, 95% CI 6.53 to 8.72). 
Consultations for pills were 4.6 times more likely to be 
delayed than those for injectables, while Christian women 
had 0.78 times the odds of delay as compared with Muslim 
women. Women with at least secondary education had 
13% lower odds of delay than women with no education. 
Although after adjusting for all other predictors the odds 
of delay peaked at the third visit and declined thereafter, 
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Table 4 Timeliness of subsequent visit for pill and injectable consultations (N=12 247 consultations)
Injectables Pills Total
n 12 237 2569 14 806
On time—no exposure to pregnancy (%) 65.1 36.3 60.1
  No delay (%)   34.8   36.3   35.0
  <4 weeks with no delay at previous consultation (%)   30.3   –   –
Delayed—exposure to pregnancy (%) 27.3 44.1 30.2
  ≥4 weeks (%)   5.4   –   –
  <4 weeks with delay at previous visit (%)   21.9   –   –
Delay status unknown (%) 7.6 19.6 9.7
this is probably an artefact of adjusting for previous delay. A 
better representation of the association between delays and 
visit number is given without adjusting for previous delay, 
showing that the second visit is least likely to be delayed, 
while the odds of delay remain higher from the third visit 
onward (see note in table 5). More of the variance in delays 
was explained by between-women variability (intraclass 
correlation=0.093) than between-facility variability (0.007).
The forward stepwise approach identified the same 
predictors in the final model.
locating missed appointments in the routines surrounding FP 
consultation attendance: insights from qualitative data
In interviews and focus group discussions, we focused on 
documenting the routines surrounding missed appoint-
ments to explore factors contributing to delays.
Knowing when to return for a follow-up consultation
Women ‘just being forgetful’ was initially mentioned by 
community members and providers as a reason for delays 
to FP appointments; however, looking more closely at 
the routines surrounding missed appointments revealed 
broader barriers to regular attendance. The ‘forgetful-
ness’ narrative makes the assumptions that women know 
(and later forget) when they need to return for a follow-up 
consultation. In contrast, it appeared that not all women 
were aware of when their next appointment was, as illus-
trated in the exchange below.
“Facilitator: Do you know the date of your next appointment?
Woman: Yes.
Facilitator: When is it?
Woman: In 2 weeks.
Interviewer: Does she [FP provider] have your appointment 
reminder card?
Woman: Yes.
Facilitator: At what time is your appointment?
[…]
Woman: I don’t know, I will go there [to the facility] and 
she will tell me.
Facilitator: So, you don’t know.
Woman: No, I forgot.” (Woman, focus group 
discussion) 
Most contraceptive users reported having an appoint-
ment reminder card filled in by the FP provider (although 
the next scheduled appointment dates recorded in 
consultation cards were sometimes wrong; providers 
sometimes rounded up to 3 months—rather than 12 
weeks—when giving three pill packs). However, illiteracy 
made some women unable to use them, particularly in 
rural areas, making them reliant on others to know their 
next appointment date, as illustrated by this woman’s 
explanation:
I do not know but I know there is still time. Since I do not 
know how to read I show the card to the literate so they can 
tell me. S. knows how to read, each time she’s the one who 
tells me my appointment [date]. (Woman, interview)
Furthermore, women using contraception without 
their relatives’ knowledge often preferred not to keep 
their appointment reminder card at home, thereby 
foregoing reminders altogether. Some providers devel-
oped practices to support women, for example keeping 
appointment reminder cards at the facility (as reported 
in the first exchange), or requesting outreach workers 
to remind them in person. Therefore, women did not 
always know their next appointment date due to being 
unable to use their appointment reminders.
Socioeconomic barriers to timely appointments
Another assumption of the ‘forgetfulness’ narrative is 
that women have the agency to return to the facility at 
the required time. In contrast, our findings highlight 
that even when women knew their next appointment 
date, they were sometimes unable to attend the facility 
on time.
Although our data show increasing acceptance of FP for 
spacing births in Senegal, a substantial number of women 
nonetheless used contraception without their husband’s 
or mother-in-law’s knowledge. Covert use appeared to 
be widespread, occurring in all regions where data were 
collected, especially (but not exclusively) in more remote 
rural areas.
[…] they do not want family planning. […] Sometimes 
when you do vaccination outreach activities in hard-to-
reach areas, you use this opportunity to offer family plan-
ning services. […] In the villages, it’s difficult. (Nurse in 
charge of health post; workshop with FP providers)
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Table 5 Predictors of delayed appointment for pills and injectables among women attending family planning (FP) 
consultations in Senegal
Predictor
Unadjusted OR
(95% CI)
Full model OR
(95% CI) Final model OR (95% CI)
Age at most recent visit 
  15–19 0.70 (0.54 to 0.92) 0.80 (0.57 to 1.11) –
  20–29 1 1 –
  30–39 1.23 (1.10 to 1.38) 1.01 (0.88 to 1.16) –
  40–50 1.37 (1.18 to 1.58) 0.91 (0.75 to 1.10) –
Number of living children 
  0–1 1 1 1
  2–3 1.14 (0.99 to 1.31) 0.95 (0.80 to 1.13) 0.99 (0.85 to 1.15)
  4+ 1.37 (1.20 to 1.58) 1.15 (0.94 to 1.41) 1.16 (0.99 to 1.35)
Ethnicity 
  Wolof 1 1 –
  Serere 0.84 (0.70 to 1.02) 0.95 (0.76 to 1.18) –
  Toucouleur 0.97 (0.81 to 1.15) 0.98 (0.80 to 1.20) –
  Mandingue/Diola/Other 0.82 (0.71 to 0.94) 0.99 (0.83 to 1.17) –
Religion 
  Muslim 1 1 1
  Christian or other 0.78 (0.63 to 0.98) 0.82 (0.63 to 1.06) 0.78 (0.61 to 0.98)
Marital status 
  Married 1 1 –
  Single, widowed, divorced, separated 0.81 (0.66 to 0.99) 0.93 (0.72 to 1.21) –
Occupation 
  Housewife 1 – –
  Student/Other 0.96 (0.85 to 1.08) – –
Education 
  None 1 1 1
  Primary 1.10 (0.97 to 1.24) 1.10 (0.96 to 1.26) 1.08 (0.95 to 1.23)
  Secondary or higher 0.84 (0.73 to 0.97) 0.89 (0.75 to 1.04) 0.87 (0.75 to 1.01)
Visit number 
  2 0.19 (.016 to 0.23) 0.60 (0.48 to 0.74)* 0.58 (0.47 to 0.70)*
  3 1 1* 1*
  4 1.10 (0.95 to 1.28) 0.78 (0.65 to 0.94)* 0.79 (0.66 to 0.94)*
  5–10 1.07 (0.95 to 1.21) 0.58 (0.50 to 0.68)* 0.58 (0.50 to 0.67)*
  11+ 1.26 (1.08 to 1.47) 0.57 (0.47 to 0.68)* 0.55 (0.46 to 0.65)*
Contraceptive method 
  Injectable 1 1 1
  Pill 3.30 (2.91 to 3.75) 4.53 (3.87 to 5.29) 4.62 (3.99 to 5.35)
Previous delay 
  None 1 1 1
  At least one 6.61 (5.98 to 7.30) 7.54 (6.47 to 8.79) 7.54 (6.53 to 8.72)
Location 
  Rural 1 – –
  Urban 1.07 (0.83 to 1.37) – –
Facility type 
  Health centre 1 1 –
  Health post 1.24 (0.95 to 1.61) 1.08 (0.92 to 1.28) –
Region 
Continued
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Predictor
Unadjusted OR
(95% CI)
Full model OR
(95% CI) Final model OR (95% CI)
  Dakar 1 1 –
  Diourbel 1.20 (0.53 to 2.72) 1.62 (0.74 to 3.55) –
  Fatick 0.78 (0.51 to 1.18) 1.04 (0.72 to 1.51) –
  Kaffrine 0.77 (0.55 to 1.06) 1.13 (0.87 to 1.47) –
  Kedougou 0.50 (0.33 to 0.77) 0.76 (0.48 to 1.19) –
  Matam 0.79 (0.55 to 1.16) 1.07 (0.75 to 1.52) –
  Sedhiou 0.65 (0.47 to 0.90) 0.93 (0.67 to 1.28) –
  Thies 0.60 (0.16 to 2.25) 1.21 (0.26 to 5.65) –
  Ziguinchor 0.64 (0.42 to 0.99) 1.04 (0.76 to 1.44) –
Percentage of months with stockouts of pills or injectables
  0%–9% 1 1 –
  10%–20% 0.82 (0.63 to 1.07) 0.95 (0.75 to 1.20)
  20% and above 0.67 (0.49 to 0.90) 0.90 (0.68 to 1.19) –
Number of FP providers 
  1–2 1 – –
  3–4 1.06 (0.80 to 1.41) – –
  5 and above 0.83 (0.62 to 1.11)
Monthly FP consultations in facility –
  0–30 1 – –
  30–80 1.18 (0.84 to 1.64) – –
  80 and above 1.05 (0.77 to 1.43) – –
Note: The full and final models include all variables with reported ORs in the relevant column.
*Visit 3 is used as the reference category for this variable since the full and final models adjust for previous delay, and it is not possible to have a 
previous delay at the second visit. The ORs for each category when previous delay is omitted from the final model are as follows: visit 2: OR=0.19 
(0.16 to 0.23); visit 3: OR=1 (reference); visit 4: OR=1.12 (0.94 to 1.33); visits 5–10: OR=1.07 (0.92 to 1.23); visits 11+: OR=1.15 (0.96 to 1.37).
Table 5 Continued
As a consequence, women reported waiting until their 
husband travelled to go to a facility, seeking FP services in 
a distant facility to avoid being identified or pretending 
to be sick as an excuse to go to a facility. Covert use 
thereby constrained when women were able to attend 
consultations, affecting the timeliness of refills. It also 
influenced contraceptive method choice, with many 
covert users preferring injectables due to their ‘invisible’ 
nature. Although some providers encouraged women to 
switch to a longer acting method in order to space their 
appointments more, in some villages there were concerns 
that such methods would be discovered by husbands.
If you see that others get Depo Provera injections, it’s be-
cause the injection does not leave any trace on the body. 
When it comes to Jadelle [implant], the men are informed 
now. They check. […] Some women use it [injection] so 
that their husbands don’t know. (Nurse in charge of health 
post; workshop with FP providers)
Beneath the logistics of missed appointments there-
fore lies the broader issue of acceptability of contracep-
tive use. Although the stigma against FP does not always 
prevent women from using contraception altogether, 
it constrains them to use injectables requiring regular 
refills and prevents them from obtaining reinjections on 
time, thereby exposing them to discontinuity in contra-
ceptive use and to pregnancy.
The cost of attending FP services was also mentioned 
as an important obstacle to timely appointments, as illus-
trated in the following focus group exchange:
“Facilitator: And you F, do you go to your appointments?
Woman 6: No.
Facilitator: Why don’t you go?
Woman 6: I don’t have any money.
Facilitator: And you B, do you go?
Woman 2: It might be that within 2 days I’ll go.
[…]
Facilitator: What are you waiting for?
Woman 2: Because of the money, because if you go there […] 
you are asked to buy a ticket [consultation fee]." 
(Women, focus group discussion) 
The total cost of services could represent substantial 
amounts: women reported having to pay up to CFA2000 
(US$3.65 equivalent) for one consultation. Within this 
context, contraception appointments were sometimes 
intentionally delayed by women in response to low cash 
flow, especially during periods of increased household 
spending such as the religious holiday of the Tabaski (Eid 
al-Adha).
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Health system barriers to timely appointments
Restricted opening hours of FP services were mentioned 
as a factor affecting missed appointments, related to 
long distances women have to travel to reach their 
nearest facility; this appeared to be especially prob-
lematic in rural areas during the harvest season when 
women worked in the fields during the day. FP services 
were not always available during health post opening 
hours. For example, midwives’ administrative and clin-
ical workload was linked to their regular absence from 
facilities, while women reported sometimes arriving at a 
facility to be asked to return on the facility’s ‘family plan-
ning day’, on a different day of the week. Furthermore, 
dépositaires (storeroom managers) managing medical 
commodities are usually paid by village health commit-
tees to be present part-time in health posts (eg, only in 
the mornings). These health systems barriers imply that 
women attending facilities may sometimes not be seen by 
a provider or receive their chosen product.
dIsCussIon
Our findings indicate that delays to women obtaining 
repeat pills and injections are common in Senegal, 
with the timing of almost one-third of all appointments 
exposing them to the risk of pregnancy. A quarter of 
injectable appointments were delayed, corresponding 
to one delayed appointment per year on average among 
the vast majority of short-acting method users. Women 
with previous delays, less education, more children, at 
least two visits and who used the pill were more likely to 
experience delays. In contrast to the prevailing narrative 
of women’s ‘forgetfulness’, broader contextual barriers 
to regular attendance emerged as the main reasons for 
missed appointments: women were not always able to use 
appointment reminders, and when they knew their next 
appointment date they sometimes had to delay attend-
ance to avoid revealing contraceptive use or in times 
of financial scarcity. The time-limited availability of FP 
services was an additional obstacle to timely contracep-
tive refills.
Similar to our findings, 16%–25% of injectable appoint-
ments occurred after the grace period in South Africa,17 
while half of first reinjections were delayed in Malawi (this 
figure does not take into account the grace period).16 The 
36% of women obtaining pill packs on time in our study 
was slightly higher than the 28% reported in Malawi.16 
For injectable users, delays resulting in pregnancy risk 
were most commonly due to repeated delays within the 
grace period at consecutive appointments, highlighting 
a potential need for better information among inject-
able users. These delays probably contribute to the high 
prevalence of unintended pregnancies in Senegal,7 29 
with important health implications in a country where 
abortion is heavily criminalised and unsafe abortion is 
common.9 30
Around 9% of appointments had an unknown delay 
status, meaning they occurred so late after the scheduled 
appointment date that women may have obtained contra-
ception elsewhere. The higher proportion of unknown 
delays for pills is consistent with the fact that they can 
be purchased in pharmacies, which are not licensed 
to administer injectables (16% of pill users nation-
ally obtained their last pack in a pharmacy).8 Many of 
these long ‘delays’ are due to women wanting to get 
pregnant; indeed, contraceptives are primarily used 
to space—rather than limit—births in Senegal,8 and 
desire for pregnancy is a primary reason for discontin-
uation in high-fertility countries.10 These interruptions 
are not problematic from a public health perspective, as 
they do not indicate an unmet need for contraception. 
Some delays may also reflect temporary discontinuation 
(‘taking a break’ from contraceptives) as a result of side 
effects, as has been described in South Africa and the 
USA.13 14
Covert use was found to be widespread in Senegal, 
echoing findings in urban Mali31 and Burkina Faso, 
where half of contraceptive users were estimated to use 
covertly in 2010,32 as well as elsewhere in sub-Saharan 
Africa.23–25 32–34 Covert use appears to be an important 
barrier to contraceptive continuity among FP users in 
our study, by depriving them of appointment reminders 
and constraining when they are able to attend the facility, 
similar to Ghana and Ethiopia where covert use was a 
risk factor for discontinuation.23 24 Acceptability remains 
an important barrier to contraceptive use in Senegal, 
despite information and advocacy efforts. A large propor-
tion of women with unmet need do not intend to use 
FP in the future,20 and opposition to contraceptive 
use is the primary reported reason for non-use among 
women and men.35 36 The slightly lower odds of delay 
among non-Muslim (predominantly Christian) women 
may reflect lower acceptability of contraception among 
the Muslim Senegalese population, or better access 
to FP among Christian women, who tend to be from 
wealthier households, larger urban centres and monoga-
mous households.37 Government, local and international 
efforts have long involved religious leaders in FP promo-
tion in Senegal, including through local ‘champion’ 
imams and pamphlets highlighting Quranic verses inter-
pretable as permitting contraception (such as women’s 
need to rest between pregnancies), in opposition to 
prevailing more conservative interpretations.38 However, 
such efforts were piecemeal and not sustained, and some 
imams continue to be vocally opposed to FP.38
Similar to findings in South Africa,17 having had a 
previous delay is a risk factor for future delays; women 
who delay appointments (intentionally or not) have a 
higher chance of facing similar circumstances at subse-
quent appointments. In our study, using the pill was 
predictive of delays. This difference is due to pill users 
becoming exposed to pregnancy shortly after their last 
pill, while injectable users are not immediately at risk 
of pregnancy; indeed, the proportion of appointments 
strictly on time was identical for both methods (36% and 
35%). Low education was identified as a contributing 
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factor to delays in qualitative and quantitative findings; 
this was not the case in Malawi16 or South Africa.17 Illit-
eracy limits the usefulness of appointment reminder 
cards for the 45% of women in the study without any 
formal education; nationally, 60% of women above 15 
are estimated to be illiterate.39 However, women with 
primary education—who are likely literate—also expe-
rienced more delays, indicating that the protective 
effect of higher education is probably due to associated 
financial, geographical or autonomy benefits, rather 
than a causal effect of literacy only.
The cost of FP services was an important barrier to 
timely contraceptive refills. Although since 2003 the 
price of pill packs and injections has been set at CFA100 
and CFA20040 (US$0.18 and US$0.36, respectively), 
FP consultation fees have not been harmonised and 
varied around CFA500 (US$0.91). This fee includes the 
cost of auxiliary products and appointment reminder 
cards in some, but not all, districts, with variable costs 
across Senegal. Overall, women reported paying up to 
CFA2000 (US$3.64) for one FP appointment, a substan-
tial barrier in a country where 38% of the population 
lives on less than US$1.90 per day41 and where women 
may not always have financial decision-making power. 
Despite funding increases since the 2012 London 
Summit, the national budget for FP remains low at 
US$13 per woman per year.42 Unlike other countries, 
FP services are not provided for free, although they are 
included under Senegal’s Universal Health Coverage 
package via community health insurance schemes. 
However, population coverage of these schemes is low 
in rural areas and the informal sector, and it is unclear 
whether they include auxiliary products.43 Health facil-
ities conduct regular outreach activities (stratégies 
avancées), although services are only provided for free 
when support is available from partner non-govern-
mental organisations (NGOs).
The use of routine FP consultation cards and quali-
tative data was a major strength of our study, enabling 
us to examine appointment behaviour among 4000 
women in 9 regions and explore factors contributing to 
delays with women and providers in 11 regions. These 
data sources provided complementary perspectives, 
identifying different risk factors: for example, oper-
ating hours and covert use were not recorded in consul-
tation cards but were identified as barriers in qualitative 
findings, highlighting the importance of using mixed 
methods to fully understand ‘missed’ appointments. 
High-quality routine data are better suited to exam-
ining gaps in continuity than self-reported contracep-
tive calendar data, which would likely underestimate 
the prevalence of delays; however, routine data have 
limitations for our analysis.
First, our identification of women attending a consul-
tation in April–June 2016 may have been incomplete. 
Although most sampled facilities appeared to imple-
ment standardised filing systems, the extent to which 
these were rigorously implemented is unknown, and 
some women may have been missed. Overall, we believe 
the ascertainment of current users was near-complete 
in most facilities. Second, there was no specific prompt 
for providers to record contraceptive method beyond 
the first visit. However, many providers recorded 
it nonetheless, and only 2% of consultations were 
excluded due to the method received being unclear. 
Extensive data quality checks and correspondence with 
midwives in Senegal ensured the data were entered and 
interpreted correctly. Records did not include other 
important information, such as parity after the first 
visit, or refills obtained from other facilities or retailers, 
although these are captured indirectly in our category 
of ‘unknown delay status’. As with many routine data 
sources, the proportion of missing data was important 
(5%–10%) for women’s sociodemographic characteris-
tics, potentially biasing our identification of risk factors, 
although we have no reason to believe that women with 
missing data are systematically different from others.
Our findings point to several recommendations 
for improving FP service delivery. More accessible FP 
service hours are needed, particularly in rural areas 
(as identified in Ghana).23 Providers should consider 
giving women more than the routine two to three pill 
packs after several months’ use without side effects to 
minimise the frequency of consultations, although the 
additional cost would likely be prohibitive for some 
women. Providers should be retrained on giving women 
the correct time to next appointment, particularly not 
rounding up the months for pills, and highlighting the 
pregnancy risk associated with repeat delays for inject-
ables. Furthermore, standardised policies to screen 
contraceptive users for risk factors (including previous 
delay, illiteracy and covert use) should be developed to 
help identify women at higher risk of delay and most 
likely to benefit from interventions to improve atten-
dance. Innovative strategies are needed for appoint-
ment reminders in settings of high illiteracy and covert 
use to improve contraceptive continuity. Existing strate-
gies for contacting women missing appointments, using 
mobile phones or community health volunteers (bajenu 
gox), should be expanded with women’s consent and 
while respecting the imperative of confidentiality. In 
light of high covert use, facilities need to ensure privacy 
and confidentiality for all women.
Nonetheless, beyond a narrow focus on individual 
women, comprehensive strategies addressing contex-
tual barriers to regular attendance are needed. In 
particular, effective, innovative interventions should be 
developed to increase the acceptability of contracep-
tive use among men and community members gener-
ally, building on existing campaigns.20 38 Cost studies 
are needed to understand how much women spend for 
FP services, transport and opportunity costs in Senegal 
and elsewhere. FP service costs should be harmonised 
nationally and auxiliary products included under the 
consultation fee across all districts. Subsidies should be 
considered to remove financial barriers for short-acting 
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methods, for example by ensuring free community 
health insurance for women least able to pay or making 
FP services free. Systematic support should be gathered 
from NGOs to ensure outreach activities in remote 
areas provide free services. Lastly, our findings echo the 
need to reinforce provision of postabortion care and 
educate providers and women on the legality of such 
care.30
ConClusIon
Our study found that pill and injectable users in Senegal 
often experience delays in their FP appointments, with 
the timing of one-third of appointments exposing them 
to pregnancy. Such gaps in continuity imply that recent 
increases in contraceptive use may not translate into 
commensurate reductions in unwanted pregnancies. 
Understanding factors contributing to short-term gaps 
in contraceptive use can also help shed light on causes 
of discontinuation. The results from this study indicate 
that women in Senegal do not always know their next 
appointment date and are not always able to attend 
the facility on time, highlighting the importance of 
addressing contextual barriers. In particular, innova-
tive interventions are needed to increase acceptability 
of contraceptive use, remind illiterate women of their 
appointments, and reduce or eliminate the cost of FP 
services.
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